Recent Company News

• 09:45 PM ET Apr 30, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 07:33 AM ET May 12, 2025
  

  Grand Pharmaceutical Group's phase III study of TLX591-CDx completes patient enrollment and dosing (HK$8.32, 0.00)

• 04:47 PM ET May 07, 2025
  

  Telix Pharmaceuticals reports peer reviewed results regarding TLX400 Published in Thyroid Journal (A$27.10, 0.00)

• 07:14 AM ET May 07, 2025
  

  NMPA approves IND of Grand Pharma's TLX591 to Phase III trial for treatment of prostate cancer (HK$6.79, 0.00)

• 07:27 PM ET Apr 28, 2025
  

  Telix Pharmaceuticals notes Illuccix has been granted marketing authorization in France (A$26.68, 0.00)

• 09:21 AM ET Apr 28, 2025
  

  StreetAccount Summary - US Pre-market trading update